PCC Rokita Future Growth

Future criteria checks 2/6

PCC Rokita is forecast to grow earnings and revenue by 14.4% and 5.6% per annum respectively. EPS is expected to grow by 24.9% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

14.4%

Earnings growth rate

24.9%

EPS growth rate

Chemicals earnings growth	21.0%
Revenue growth rate	5.6%
Future return on equity	11.4%
Analyst coverage	Low
Last updated	26 Nov 2024

Recent future growth updates

Recent updates

Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

May 30

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Aug 24

PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 29

PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Mar 09

Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

Feb 19

What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

Feb 04

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Jan 15

Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Dec 30

Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

Dec 17

PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Dec 03

Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Nov 20

Earnings and Revenue Growth Forecasts

WSE:PCR - Analysts future estimates and past financials data (PLN Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,378	189	173	376	3
12/31/2025	2,249	122	127	278	3
12/31/2024	1,952	90	98	302	2
9/30/2024	1,995	121	188	335	N/A
6/30/2024	2,048	158	212	376	N/A
3/31/2024	2,100	144	111	310	N/A
12/31/2023	2,388	268	296	512	N/A
9/30/2023	2,782	473	511	736	N/A
6/30/2023	3,072	589	623	883	N/A
3/31/2023	3,225	692	691	941	N/A
12/31/2022	3,143	675	563	792	N/A
9/30/2022	2,821	569	392	621	N/A
6/30/2022	2,560	499	383	575	N/A
3/31/2022	2,405	472	399	553	N/A
12/31/2021	2,203	417	380	530	N/A
9/30/2021	2,027	294	328	468	N/A
6/30/2021	1,827	247	267	389	N/A
3/31/2021	1,597	171	200	342	N/A
12/31/2020	1,476	117	195	366	N/A
9/30/2020	1,414	73	149	340	N/A
6/30/2020	1,461	82	136	357	N/A
3/31/2020	1,482	72	123	355	N/A
12/31/2019	1,492	93	77	310	N/A
9/30/2019	1,513	145	81	316	N/A
6/30/2019	1,503	160	55	295	N/A
3/31/2019	1,512	201	82	356	N/A
12/31/2018	1,490	227	41	287	N/A
9/30/2018	1,445	243	18	254	N/A
6/30/2018	1,378	215	N/A	220	N/A
3/31/2018	1,345	213	N/A	181	N/A
12/31/2017	1,286	182	N/A	204	N/A
9/30/2017	1,234	208	N/A	264	N/A
6/30/2017	1,187	213	N/A	264	N/A
3/31/2017	1,129	207	N/A	259	N/A
12/31/2016	1,107	203	N/A	263	N/A
9/30/2016	1,084	135	N/A	220	N/A
6/30/2016	1,097	131	N/A	187	N/A
3/31/2016	1,077	110	N/A	161	N/A
12/31/2015	1,049	85	N/A	149	N/A
9/30/2015	1,053	73	N/A	123	N/A
6/30/2015	1,062	62	N/A	130	N/A
3/31/2015	1,083	62	N/A	119	N/A
12/31/2014	1,093	71	N/A	165	N/A
9/30/2014	1,066	58	N/A	117	N/A
6/30/2014	1,041	48	N/A	96	N/A
3/31/2014	1,085	52	N/A	98	N/A
12/31/2013	1,101	58	N/A	104	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCR's forecast earnings growth (14.4% per year) is above the savings rate (4.1%).

Earnings vs Market: PCR's earnings (14.4% per year) are forecast to grow slower than the Polish market (15.9% per year).

High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.

Revenue vs Market: PCR's revenue (5.6% per year) is forecast to grow faster than the Polish market (4.8% per year).

High Growth Revenue: PCR's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (11.4%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 02:51
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PCC Rokita SA is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lukasz Prokopiuk	Dom Maklerski Banku Ochrony Srodowiska S.A.
Tomasz Duda	Erste Group Bank AG
Jakub Szkopek	Erste Group Bank AG

PCC Rokita Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 27%

Price target increased to zł126

Price target increased to zł75.20

Price target raised to zł53.69

Recent updates

Third quarter 2024 earnings released: zł0.38 loss per share (vs zł1.50 profit in 3Q 2023)

Consensus EPS estimates fall by 27%

Second quarter 2024 earnings released: EPS: zł1.50 (vs zł0.76 in 2Q 2023)

Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?

First quarter 2024 earnings released: EPS: zł0.82 (vs zł7.08 in 1Q 2023)

PCC Rokita SA, Annual General Meeting, May 20, 2024

Full year 2023 earnings released: EPS: zł13.49 (vs zł34.00 in FY 2022)

PCC Rokita SA to Report Q3, 2024 Results on Nov 14, 2024

Third quarter 2023 earnings released

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

Second quarter 2023 earnings released

First quarter 2023 earnings released

Investor sentiment deteriorates as stock falls 17%

PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings released: EPS: zł34.00 (vs zł21.02 in FY 2021)

Investor sentiment improves as stock rises 19%

PCC Rokita SA to Report Q2, 2023 Results on Aug 22, 2023

Is PCC Rokita (WSE:PCR) A Risky Investment?

Third quarter 2022 earnings released

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

First quarter 2022 earnings released

Price target increased to zł126

Upcoming dividend of zł13.23 per share

PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23

Why We Like The Returns At PCC Rokita (WSE:PCR)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?

Third quarter 2021 earnings released

We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)

Second quarter 2021 earnings released

Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching

Price target increased to zł75.20

Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?

Upcoming dividend of zł3.67 per share

PCC Rokita Announces Dividend for the Year 2020, Payable on May 14, 2021

Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes

Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem

Full year 2020 earnings released: EPS zł5.91 (vs zł4.70 in FY 2019)

PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

New 90-day high: zł73.60

Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?

What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?

New 90-day high: zł65.80

PCC Rokita SA to Report Fiscal Year 2020 Results on Mar 16, 2021

PCC Rokita SA to Report Q2, 2021 Results on Aug 18, 2021

Is PCC Rokita (WSE:PCR) Using Too Much Debt?

New 90-day high: zł56.80

Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?

Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years

New 90-day high: zł49.10

PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?

Third quarter 2020 earnings released: EPS zł1.47

New 90-day low: zł41.40

Price target raised to zł53.69

New 90-day low: zł42.10

Earnings released

New 90-day high - zł49.40

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources